Drugs / NNC0480-0389
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05498610 | Aug → Oct 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05153564 | Dec 2021 → Aug 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05015894 | Aug 2021 → Aug 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04878406 | May → Jul 2021 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04259801 | Feb 2020 → Mar 2022 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05144984 | Nov 2021 → Feb 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05046873 Comparator | Sep 2021 → Jan 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC04800389 | “The participants will be administered 0.5 mg semaglutide and 5 mg NNC0480 0389 as an subcutaneus injection (s.c.) on two separate dosing visits separated by at least 8 weeks.” NCT05046873 ↗8“Participants will get 1 injections of NNC04800389.” NCT05498610 ↗ |
| Route | Subcutaneous | “Part 1: 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.” NCT04259801 ↗ |